Why this could be a 'powerful driver of sector dominance' for CSL shares: Wilsons

Broker Wilsons says CSL's newly approved haemophilia B treatment is a game-changer in that market.

| More on:
A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Top broker Wilsons says CSL has a 'powerful driver of sector dominance' with its new haemophilia B treatment called Hemgenix 
  • Hemgenix has just been approved by the United States Food and Drug Administration 
  • Wilsons thinks CSL shares can go well above the $300 threshold over the next year 

The CSL Limited (ASX: CSL) share price is holding above the $300 mark today, up 0.77% to $301.33 at lunchtime. Meantime the S&P/ASX 200 Index (ASX: XJO) is also in the green by 0.19%.

It's been an exciting couple of days for the ASX healthcare share. CSL's unique haemophilia B treatment, called Hemgenix, has just received approval from the United States Food and Drug Administration.

CSL CEO Paul Perreault describes the decision as a "historic approval". This is because Hemgenix is the first and only one-time gene therapy to become available for adults with haemophilia B.

A commercial launch is expected in FY24.

What does this mean for the CSL share price?

According to The Australian, Wilsons analyst Shane Storey says Hemgenix is a "powerful driver of sector dominance" for CSL.

Storey said:

Hemgenix will open up the haemophilia B market to a younger cohort of patients that exhibit suboptimal adherence to prophylactic therapy due to the onerous nature of delivery.

The potential to replace ≥10 years of regular prophylactic management for these patients with a single shot of Hemgenix is a powerful driver of sector dominance, which brings with it margin expansion and sales leverage opportunities within the CSL Behring recombinant haemophilia (rHaem) portfolio.

CSL is already a market leader in haemophilia treatments. It has a drug called Idelvion, which extends the half-life of factor IX infusions, meaning patients need less frequent treatment (every 14 days).

Wilsons is tipping a 12-month share price target of $327 for CSL shares and has an overweight rating.

As my colleague James reported today, Citi has reaffirmed its buy rating and share price target of $340.

Macquarie is retaining its outperform rating but has lifted its price target by 4.1% to $343.

How does Hemgenix work?

Haemophilia is a blood disorder caused by a genetic defect that stops the body from creating its own coagulating factors.

Haemophilia A means low factor VIII and haemophilia B means low factor IX.

The factors are proteins that help the blood coagulate. Without them, the blood gets too thin and this can lead to bleeding.

One of the most common treatments to date is regular factor infusions. Even then, patients can still experience spontaneous bleeds, leading to problems like joint damage and strong pain.

Hemgenix can stop spontaneous bleeds in haemophilia B patients by prompting the body to produce its own factor IX.

The Australian quotes Kim Phelan, chief operating officer of The Coalition for Haemophilia B, who said gene therapy offered "the possibility of freedom from the need for regular, ongoing infusions".

The European Medicines Agency is also reviewing Hemgenix for approval.

CSL shares snapshot

CSL shares crossed the $300 mark this week for only the third time in 2022.

Prior to COVID-19, the CSL share price was trading up around $340 before the market crash.

Since then, it has risen above $300 several times but hasn't been able to stay there.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. and Macquarie Group Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »